- Home
- CII vs ZYME Comparison
CII vs ZYME Comparison
Compare CII & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CII
- ZYME
- Stock Information
- Founded
- CII 2004
- ZYME 2003
- Country
- CII United States
- ZYME United States
- Employees
- CII N/A
- ZYME N/A
- Industry
- CII Investment Bankers/Brokers/Service
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- CII Finance
- ZYME Health Care
- Exchange
- CII Nasdaq
- ZYME Nasdaq
- Market Cap
- CII 860.9M
- ZYME 751.6M
- IPO Year
- CII N/A
- ZYME 2017
- Fundamental
- Price
- CII $19.82
- ZYME $14.14
- Analyst Decision
- CII
- ZYME Buy
- Analyst Count
- CII 0
- ZYME 6
- Target Price
- CII N/A
- ZYME $19.17
- AVG Volume (30 Days)
- CII 78.8K
- ZYME 505.4K
- Earning Date
- CII 01-01-0001
- ZYME 10-31-2024
- Dividend Yield
- CII 6.17%
- ZYME N/A
- EPS Growth
- CII N/A
- ZYME N/A
- EPS
- CII N/A
- ZYME N/A
- Revenue
- CII N/A
- ZYME $62,199,000.00
- Revenue This Year
- CII N/A
- ZYME $21.53
- Revenue Next Year
- CII N/A
- ZYME N/A
- P/E Ratio
- CII N/A
- ZYME N/A
- Revenue Growth
- CII N/A
- ZYME N/A
- 52 Week Low
- CII $16.76
- ZYME $7.97
- 52 Week High
- CII $19.81
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- CII 45.22
- ZYME 52.72
- Support Level
- CII $19.44
- ZYME $12.48
- Resistance Level
- CII $20.46
- ZYME $14.10
- Average True Range (ATR)
- CII 0.25
- ZYME 0.72
- MACD
- CII -0.08
- ZYME 0.02
- Stochastic Oscillator
- CII 37.25
- ZYME 81.43
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.